Boston Scientific(BSX) Prnewswire·2025-04-23 10:45Core Viewpoint - Boston Scientific Corporation announces the retirement of Dan Brennan, the executive vice president and chief financial officer, after nearly 30 years with the company, effective at the end of June 2025, with a transition period as a senior advisor until early October 2025 [1][2] Company Leadership Transition - Jon Monson, currently senior vice president of Investor Relations, will succeed Dan Brennan as executive vice president and CFO, effective June 30, 2025, reporting to CEO Mike Mahoney [2][3] - Brennan and Monson will collaborate closely to ensure a smooth transition, with Monson taking on responsibilities including global controllership, corporate finance, and corporate business development [2][3] Dan Brennan's Contributions - Dan Brennan has been recognized for his exceptional leadership and contributions to Boston Scientific, particularly in transforming the company's financial performance and developing talent within the financial organization [2][3] - Under Brennan's leadership since 2014, the company has overseen numerous strategic investment opportunities [2] Jon Monson's Background - Jon Monson has over 25 years of experience with Boston Scientific, having held various roles in finance, including global controller and chief accounting officer [3] - He is a certified public accountant with a Bachelor of Arts degree in economics and accounting from the College of the Holy Cross [3] Company Overview - Boston Scientific is a global leader in medical technology, providing innovative solutions to improve patient health and reduce healthcare costs [4] - The company has been advancing science for life for over 45 years, offering a wide range of devices and therapies for various medical conditions [4]